Trial Profile

VIC Regimen (Vemurafenib/Irinotecan/Cetuximab) Versus Bevacizumab Plus Chemotherapy as First-Line Treatment for BRAF V600E-Mutated Advanced Colorectal Cancer

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 15 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cetuximab (Primary) ; Irinotecan (Primary) ; Vemurafenib (Primary) ; Antineoplastics; Bevacizumab
Indications Adenocarcinoma; Colorectal cancer
Focus Therapeutic Use

24 Oct 2023 Results comparing compare the efficacy and safety of the Vemurafenib/Irinotecan/Cetuximab regimen versus bevacizumab plus chemotherapy as first-line setting in Asian patients, presented at the 48th European Society for Medical Oncology Congress.
06 Jun 2023 Primary endpoint has been met. (objective response rate), as per results presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
06 Jun 2023 Primary endpoint has been met. (overall survival), as per results presented at the 59th Annual Meeting of the American Society of Clinical Oncology.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com